Symbols / CRDL $1.39 -1.42% Cardiol Therapeutics Inc.
CRDL Chart
About
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 155.24M |
| Enterprise Value | 116.81M | Income | -33.82M | Sales | — |
| Book/sh | 0.08 | Cash/sh | 0.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -5.76 | PEG | — |
| P/S | — | P/B | 17.73 | P/C | — |
| EV/EBITDA | -3.41 | EV/Sales | — | Quick Ratio | 3.83 |
| Current Ratio | 4.16 | Debt/Eq | 0.70 | LT Debt/Eq | — |
| EPS (ttm) | -0.28 | EPS next Y | -0.24 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -77.31% |
| ROE | -158.75% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 111.68M |
| Shs Float | 84.36M | Short Float | 1.93% | Short Ratio | 6.25 |
| Short Interest | — | 52W High | 1.59 | 52W Low | 0.80 |
| Beta | — | Avg Volume | 564.41K | Volume | 606.21K |
| Target Price | $7.40 | Recom | Strong_buy | Prev Close | $1.41 |
| Price | $1.39 | Change | -1.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.40
Mean price target
2. Current target
$1.39
Latest analyst target
3. DCF / Fair value
$-3.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.39
Low
$4.89
High
$9.00
Mean
$7.40
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-06 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-12-01 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-06-02 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-26 | init | Roth MKM | — → Buy | $10 |
| 2024-06-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-07 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-23 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-04-22 | init | HC Wainwright & Co. | — → Buy | $9 |
- CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill hu, 02 Apr 2026 07
- Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus Mon, 06 Apr 2026 18
- Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat Mon, 06 Apr 2026 15
- Heart drug trial passes halfway mark as Cardiol funds work into 2027 - Stock Titan Wed, 01 Apr 2026 11
- Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long - Yahoo Finance Mon, 12 Jan 2026 08
- Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - TMX Newsfile Fri, 23 Jan 2026 08
- Should you sell your Cardiol Therapeutics stock? - Cantech Letter hu, 04 Dec 2025 08
- CRDL Stock Rating Reiterated at 'Buy' by HC Wainwright & Co. | C - GuruFocus ue, 10 Feb 2026 08
- What is HC Wainwright's Estimate for CRDL FY2028 Earnings? - MarketBeat Fri, 03 Apr 2026 11
- CRDL SEC Filings - Cardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 20 Mar 2026 00
- Cardiol Therapeutics (NASDAQ:CRDL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat Wed, 01 Apr 2026 15
- Heart drug developer Cardiol lines up $13.5M to fund trials and research - Stock Titan Fri, 16 Jan 2026 08
- Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat Sun, 05 Apr 2026 05
- Cardiol Therapeutics (NASDAQ: CRDL) advances 2025 cardiac trials and funding - Stock Titan Wed, 01 Apr 2026 11
- Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results - Stock Titan ue, 31 Mar 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
34.32
-14.80%
|
40.28
+35.22%
|
29.79
-27.94%
|
41.34
|
| Research And Development |
|
14.02
+0.05%
|
14.01
-1.49%
|
14.22
-24.99%
|
18.96
|
| Selling General And Administration |
|
20.20
-22.00%
|
25.89
+66.38%
|
15.56
-30.45%
|
22.37
|
| General And Administrative Expense |
|
20.20
-22.00%
|
25.89
+66.38%
|
15.56
-30.45%
|
22.37
|
| Salaries And Wages |
|
9.22
-28.59%
|
12.92
|
—
|
—
|
| Other Gand A |
|
10.97
-15.44%
|
12.97
-16.62%
|
15.56
-30.45%
|
22.37
|
| Total Expenses |
|
34.32
-14.80%
|
40.28
+35.22%
|
29.79
-27.94%
|
41.34
|
| Operating Income |
|
-34.32
+14.80%
|
-40.28
-35.22%
|
-29.79
+27.94%
|
-41.34
|
| EBITDA |
|
-34.21
+14.26%
|
-39.90
-35.10%
|
-29.54
+28.16%
|
-41.12
|
| Normalized EBITDA |
|
-33.99
+19.62%
|
-42.28
-45.77%
|
-29.01
+42.13%
|
-50.12
|
| Reconciled Depreciation |
|
0.10
-72.67%
|
0.37
+50.23%
|
0.25
+12.94%
|
0.22
|
| EBIT |
|
-34.32
+14.80%
|
-40.28
-35.22%
|
-29.79
+27.94%
|
-41.34
|
| Total Unusual Items |
|
-0.23
-109.63%
|
2.38
+547.80%
|
-0.53
-105.90%
|
9.00
|
| Total Unusual Items Excluding Goodwill |
|
-0.23
-109.63%
|
2.38
+547.80%
|
-0.53
-105.90%
|
9.00
|
| Net Income |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Pretax Income |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Net Non Operating Interest Income Expense |
|
0.73
-39.13%
|
1.19
-41.46%
|
2.04
+64.71%
|
1.24
|
| Net Interest Income |
|
0.73
-39.13%
|
1.19
-41.46%
|
2.04
+64.71%
|
1.24
|
| Interest Income Non Operating |
|
0.73
-39.13%
|
1.19
-41.46%
|
2.04
+64.71%
|
1.24
|
| Interest Income |
|
0.73
-39.13%
|
1.19
-41.46%
|
2.04
+64.71%
|
1.24
|
| Other Income Expense |
|
-0.23
-109.52%
|
2.41
+731.08%
|
-0.38
-104.16%
|
9.17
|
| Other Non Operating Income Expenses |
|
—
|
0.03
-81.15%
|
0.15
-8.94%
|
0.16
|
| Gain On Sale Of Security |
|
-0.23
-109.63%
|
2.38
+547.80%
|
-0.53
-105.90%
|
9.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Net Income From Continuing Operation Net Minority Interest |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Net Income From Continuing And Discontinued Operation |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Net Income Continuous Operations |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Normalized Income |
|
-33.59
+13.99%
|
-39.06
-41.52%
|
-27.60
+30.89%
|
-39.93
|
| Net Income Common Stockholders |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Diluted EPS |
|
-0.39
+23.53%
|
-0.51
-15.91%
|
-0.44
+10.20%
|
-0.49
|
| Basic EPS |
|
-0.39
+23.53%
|
-0.51
-15.91%
|
-0.44
+10.20%
|
-0.49
|
| Basic Average Shares |
|
86.99
+21.55%
|
71.57
+11.02%
|
64.46
+3.13%
|
62.51
|
| Diluted Average Shares |
|
86.99
+21.55%
|
71.57
+11.02%
|
64.46
+3.13%
|
62.51
|
| Diluted NI Availto Com Stockholders |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Amortization |
|
0.00
-100.00%
|
0.21
|
—
|
—
|
| Amortization Of Intangibles Income Statement |
|
0.00
-100.00%
|
0.21
|
—
|
—
|
| Depreciation Amortization Depletion Income Statement |
|
0.10
-72.67%
|
0.37
|
—
|
—
|
| Depreciation And Amortization In Income Statement |
|
0.10
-72.67%
|
0.37
|
—
|
—
|
| Depreciation Income Statement |
|
0.10
-37.34%
|
0.16
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
23.62
-25.87%
|
31.86
-13.18%
|
36.70
-40.83%
|
62.03
|
| Current Assets |
|
23.50
-25.79%
|
31.67
-12.41%
|
36.15
-41.16%
|
61.44
|
| Cash Cash Equivalents And Short Term Investments |
|
21.42
-29.97%
|
30.58
-12.46%
|
34.93
-41.26%
|
59.47
|
| Cash And Cash Equivalents |
|
21.42
-29.97%
|
30.58
-12.46%
|
34.93
-41.26%
|
59.47
|
| Receivables |
|
0.23
-37.45%
|
0.36
+29.21%
|
0.28
-41.72%
|
0.48
|
| Accounts Receivable |
|
0.06
-44.48%
|
0.10
-29.69%
|
0.14
-32.00%
|
0.21
|
| Other Receivables |
|
0.17
-34.75%
|
0.26
+90.52%
|
0.14
-49.26%
|
0.27
|
| Prepaid Assets |
|
1.86
+155.88%
|
0.73
-22.83%
|
0.94
-36.73%
|
1.49
|
| Total Non Current Assets |
|
0.12
-39.62%
|
0.20
-64.27%
|
0.55
-7.30%
|
0.59
|
| Net PPE |
|
0.12
-39.62%
|
0.20
-41.97%
|
0.34
+13.97%
|
0.30
|
| Gross PPE |
|
0.99
+2.53%
|
0.97
-2.57%
|
0.99
+26.03%
|
0.79
|
| Accumulated Depreciation |
|
-0.87
-13.20%
|
-0.77
-17.65%
|
-0.66
-33.26%
|
-0.49
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.24
+11.29%
|
0.22
+10.89%
|
0.20
+9.14%
|
0.18
|
| Other Properties |
|
0.51
+0.00%
|
0.51
-8.35%
|
0.56
+50.74%
|
0.37
|
| Leases |
|
0.24
+0.00%
|
0.24
+0.00%
|
0.24
+0.00%
|
0.24
|
| Goodwill And Other Intangible Assets |
|
—
|
0.00
-100.00%
|
0.21
-28.64%
|
0.29
|
| Other Intangible Assets |
|
—
|
—
|
0.21
-28.64%
|
0.29
|
| Total Liabilities Net Minority Interest |
|
5.74
-19.52%
|
7.14
-15.60%
|
8.45
-13.97%
|
9.83
|
| Current Liabilities |
|
5.66
-19.33%
|
7.01
-15.50%
|
8.30
-15.39%
|
9.80
|
| Payables And Accrued Expenses |
|
3.48
-50.14%
|
6.98
-13.24%
|
8.04
-13.85%
|
9.33
|
| Current Debt And Capital Lease Obligation |
|
0.04
+16.17%
|
0.03
+108.81%
|
0.02
-68.66%
|
0.05
|
| Current Capital Lease Obligation |
|
0.04
+16.17%
|
0.03
+108.81%
|
0.02
-68.66%
|
0.05
|
| Other Current Liabilities |
|
2.14
|
—
|
0.24
-43.28%
|
0.42
|
| Total Non Current Liabilities Net Minority Interest |
|
0.09
-30.55%
|
0.13
-20.82%
|
0.16
+606.97%
|
0.02
|
| Long Term Debt And Capital Lease Obligation |
|
0.09
-30.55%
|
0.13
-20.82%
|
0.16
+606.97%
|
0.02
|
| Long Term Capital Lease Obligation |
|
0.09
-30.55%
|
0.13
-20.82%
|
0.16
+606.97%
|
0.02
|
| Stockholders Equity |
|
17.88
-27.70%
|
24.73
-12.45%
|
28.25
-45.89%
|
52.20
|
| Common Stock Equity |
|
17.88
-27.70%
|
24.73
-12.45%
|
28.25
-45.89%
|
52.20
|
| Capital Stock |
|
201.87
+12.56%
|
179.34
+20.75%
|
148.52
+0.66%
|
147.55
|
| Common Stock |
|
201.87
+12.56%
|
179.34
+20.75%
|
148.52
+0.66%
|
147.55
|
| Share Issued |
|
100.26
+21.36%
|
82.61
+26.41%
|
65.35
+2.05%
|
64.04
|
| Ordinary Shares Number |
|
100.26
+21.36%
|
82.61
+26.41%
|
65.35
+2.05%
|
64.04
|
| Additional Paid In Capital |
|
29.08
+18.00%
|
24.65
+31.20%
|
18.79
+20.53%
|
15.59
|
| Retained Earnings |
|
-213.07
-18.87%
|
-179.25
-25.72%
|
-142.58
-24.58%
|
-114.45
|
| Total Equity Gross Minority Interest |
|
17.88
-27.70%
|
24.73
-12.45%
|
28.25
-45.89%
|
52.20
|
| Total Capitalization |
|
17.88
-27.70%
|
24.73
-12.45%
|
28.25
-45.89%
|
52.20
|
| Working Capital |
|
17.85
-27.62%
|
24.66
-11.48%
|
27.86
-46.05%
|
51.63
|
| Invested Capital |
|
17.88
-27.70%
|
24.73
-12.45%
|
28.25
-45.89%
|
52.20
|
| Total Debt |
|
0.13
-20.82%
|
0.16
-9.07%
|
0.17
+139.24%
|
0.07
|
| Capital Lease Obligations |
|
0.13
-20.82%
|
0.16
-9.07%
|
0.17
+139.24%
|
0.07
|
| Net Tangible Assets |
|
17.88
-27.70%
|
24.73
-11.80%
|
28.04
-45.99%
|
51.91
|
| Tangible Book Value |
|
17.88
-27.70%
|
24.73
-11.80%
|
28.04
-45.99%
|
51.91
|
| Other Equity Interest |
|
—
|
—
|
3.52
+0.00%
|
3.52
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-23.85
+4.81%
|
-25.06
+0.47%
|
-25.18
+7.49%
|
-27.22
|
| Cash Flow From Continuing Operating Activities |
|
-23.85
+4.81%
|
-25.06
+0.47%
|
-25.18
+7.49%
|
-27.22
|
| Net Income From Continuing Operations |
|
-33.82
+7.79%
|
-36.68
-30.39%
|
-28.13
+9.06%
|
-30.93
|
| Depreciation Amortization Depletion |
|
0.10
-72.67%
|
0.37
+50.23%
|
0.25
+12.94%
|
0.22
|
| Depreciation |
|
0.10
-37.34%
|
0.16
-0.70%
|
0.16
+21.00%
|
0.14
|
| Amortization Cash Flow |
|
0.00
-100.00%
|
0.21
+149.11%
|
0.08
+0.00%
|
0.08
|
| Depreciation And Amortization |
|
0.10
-72.67%
|
0.37
+50.23%
|
0.25
+12.94%
|
0.22
|
| Amortization Of Intangibles |
|
0.00
-100.00%
|
0.21
+149.11%
|
0.08
+0.00%
|
0.08
|
| Other Non Cash Items |
|
0.02
-13.05%
|
0.03
-20.54%
|
0.03
-93.94%
|
0.53
|
| Stock Based Compensation |
|
10.70
-25.05%
|
14.28
+243.47%
|
4.16
-17.08%
|
5.01
|
| Operating Gains Losses |
|
-0.13
+94.00%
|
-2.13
-125.51%
|
-0.94
+87.91%
|
-7.81
|
| Gain Loss On Investment Securities |
|
-0.95
-299.60%
|
-0.24
-31.06%
|
-0.18
+96.28%
|
-4.89
|
| Net Foreign Currency Exchange Gain Loss |
|
0.82
+143.60%
|
-1.89
-148.03%
|
-0.76
+73.90%
|
-2.92
|
| Change In Working Capital |
|
-0.73
+21.28%
|
-0.93
-70.65%
|
-0.55
-109.50%
|
5.75
|
| Change In Receivables |
|
0.14
+265.66%
|
-0.08
-140.81%
|
0.20
+374.15%
|
-0.07
|
| Changes In Account Receivables |
|
0.04
+5.33%
|
0.04
-36.92%
|
0.07
+146.59%
|
-0.14
|
| Change In Inventory |
|
—
|
—
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
-1.13
-626.89%
|
0.21
-60.67%
|
0.55
-59.41%
|
1.35
|
| Change In Payables And Accrued Expense |
|
0.26
+124.77%
|
-1.06
+17.63%
|
-1.29
-128.89%
|
4.47
|
| Investing Cash Flow |
|
-0.02
-15.00%
|
-0.02
+66.90%
|
-0.06
+13.92%
|
-0.07
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
-15.00%
|
-0.02
+66.90%
|
-0.06
+13.92%
|
-0.07
|
| Net PPE Purchase And Sale |
|
-0.02
-15.00%
|
-0.02
+66.90%
|
-0.06
+13.92%
|
-0.07
|
| Purchase Of PPE |
|
-0.02
-15.00%
|
-0.02
+66.90%
|
-0.06
+13.92%
|
-0.07
|
| Capital Expenditure |
|
-0.02
-15.00%
|
-0.02
+66.90%
|
-0.06
+13.92%
|
-0.07
|
| Financing Cash Flow |
|
15.54
-17.52%
|
18.84
+34122.57%
|
-0.06
-2.67%
|
-0.05
|
| Cash Flow From Continuing Financing Activities |
|
15.54
-17.52%
|
18.84
+34122.57%
|
-0.06
-2.67%
|
-0.05
|
| Net Issuance Payments Of Debt |
|
-0.06
-33.33%
|
-0.04
+25.00%
|
-0.06
-2.67%
|
-0.05
|
| Repayment Of Debt |
|
-0.06
-33.33%
|
-0.04
+25.00%
|
-0.06
-2.67%
|
-0.05
|
| Long Term Debt Payments |
|
-0.06
-33.33%
|
-0.04
+25.00%
|
-0.06
-2.67%
|
-0.05
|
| Net Long Term Debt Issuance |
|
-0.06
-33.33%
|
-0.04
+25.00%
|
-0.06
-2.67%
|
-0.05
|
| Net Common Stock Issuance |
|
16.04
-24.90%
|
21.36
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.03
-80.70%
|
0.18
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-0.48
+82.01%
|
-2.65
|
—
|
—
|
| Changes In Cash |
|
-8.34
-33.60%
|
-6.24
+75.33%
|
-25.30
+7.49%
|
-27.35
|
| Effect Of Exchange Rate Changes |
|
-0.82
-143.60%
|
1.89
+148.03%
|
0.76
-73.90%
|
2.92
|
| Beginning Cash Position |
|
30.58
-12.46%
|
34.93
-41.26%
|
59.47
-29.12%
|
83.90
|
| End Cash Position |
|
21.42
-29.97%
|
30.58
-12.46%
|
34.93
-41.26%
|
59.47
|
| Free Cash Flow |
|
-23.88
+4.80%
|
-25.08
+0.64%
|
-25.24
+7.51%
|
-27.30
|
| Common Stock Issuance |
|
16.04
-24.90%
|
21.36
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
16.04
-24.90%
|
21.36
|
0.00
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|